Thromb Haemost 1999; 81(03): 475-476
DOI: 10.1055/s-0037-1614506
Letters to the Editor
Schattauer GmbH

Prevalence of Factor VIII Inhibitors in Patients with Hemophilia A in Brazil

Alexandre Rieger
1   From the Department of Genetics, Hemostasis Laboratory, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil
,
Israel Roisenberg
1   From the Department of Genetics, Hemostasis Laboratory, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil
› Author Affiliations
Further Information

Publication History

Received31 March 1998

Accepted after resubmission22 October 1998

Publication Date:
09 December 2017 (online)

 

 
  • References

  • 1 Aledort LM.. World registry on factor VIII inhibitor patients. Why?. Semin Hematol 1993; 30 (Suppl. 01) Suppl 7-9.
  • 2 Briët E, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K, Vermylen J, Ljung R, Rocino A, Addiego J, Lorenzo JI, Pabinger I.. High titer inhibitors in severe haemophilia A (Letter to the Editor). Thromb Haemost 1994; 72: 162-4.
  • 3 Hoyer LW.. The incidence of factor VIII inhibitors in patients with severe hemophilia A. Adv Exp Med Biol 1995; 386: 34-45.
  • 4 Kreuz W, Becker S, Lenz E, Martinez-Saguer I, Escuriola-Ettingshausen C, Funk M, Ehrenforth S, Auerswald G, Kornhuber B.. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Semin Thromb Hemost 1995; 21: 382-9.
  • 5 Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Güngör T, Korn-huber B.. Epidemiology of inhibitors in haemophilia A. Vox Sang 1996; 70 (Suppl. 01) Suppl 2-8.
  • 6 Zupancic-Salek S, Sertic D, Brkljacic V.. Prevalence of inhibitors specific for factor VIII in multitransfused haemophiliacs A. Br J Haematol 1994; 87 (Suppl. 01) Suppl 191 (Abstract).
  • 7 Rasi V, Ikkala E.. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-71
  • 8 Kasper C, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Schulman NR, Eys JVA.. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemost 1975; 34: 869-72.
  • 9 Peerlinck K, Rosendaal FR, Vermylen J.. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993; 81: 3332-5.
  • 10 White II GC, McMillan CW, Blatt PM, Roberts HR.. Factor VIII inhibitors: a clinical overwiew. Am J Hematol 1982; 13: 335-42.
  • 11 McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. and the Hemophilia Study Group. The natural history of factor VIII:C inhibitors in patients with hemophilia A: A national cooperative study. II. Observation on the initial development of factor VIII.C inhibitors. Blood 1988; 71: 344-8.
  • 12 Sultan Y. and the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67: 600-2.